Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model

Intrahepatic cholangiocarcinoma (iCCA) is a deadly malignancy with limited treatment options. Gain-of-function mutations in K-Ras is a very frequent alteration, occurring in ~15 to 25% of human iCCA patients. Here, we established a new iCCA model by expressing activated forms of Notch1 (NICD) and K-...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Mingjie, Liu, Xianqiong, Evert, Katja, Utpatel, Kirsten, Peters, Michele, Zhang, Shanshan, Xu, Zhong, Che, Li, Cigliano, Antonio, Ribback, Silvia, Dombrowski, Frank, Cossu, Antonio, Gordan, John, Calvisi, Diego F., Evert, Matthias, Liu, Yan, Chen, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833851/
https://www.ncbi.nlm.nih.gov/pubmed/29348467
http://dx.doi.org/10.1038/s41419-017-0183-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833851/
https://www.ncbi.nlm.nih.gov/pubmed/29348467
http://dx.doi.org/10.1038/s41419-017-0183-4

Ejemplares similares